Thus, an increase of indolelactic acid in the intervention group's plasma could alleviate NAFLD by enhancing the stimulation of mucosal defense, modulating inflammatory responses, and glucose homeostasis in an AhR-dependent manner. This evidence concerns the gene AHR and metabolic dysfunction-associated steatotic liver disease.